Every letter we have printed

You describe the low-T3 pattern during energy restriction as benign adaptation. There is a body of opinion holding that it represents a genuine hypometabolic state requiring treatment. I do not hold that view but your readers will encounter it.

My HbA1c was 6.1 before starting and 6.0 after four months. My clinic recorded this as no improvement in glycaemic control. My continuous monitor says my average glucose fell by a fifth over the same period. Which is measuring what?

Correction to your HbA1c section. You write that chronic kidney disease lowers HbA1c through shortened erythrocyte survival. It can also raise measured values on some assay platforms through carbamylated haemoglobin interference. The net direction depends on the method.

Your needle-length section says four millimetres is adequate for all adults, which contradicts what I was told by a nurse who insisted on half an inch because of my weight. Which is right?

You recommend writing the concentration on the vial. I would add: write it on the box as well. My vial label came off in the fridge and I lost the only record of what diluent volume I had used.

Nothing in this file addresses what to do when you realise mid-week that you have made an error. I gave double my dose on a Sunday and could find no guidance anywhere about what that meant.

I gave myself a tenth of my intended dose for five weeks. I had been using insulin syringes, ran out, and used the 1 mL syringes that came with the vials, which are marked in millilitres. I did not notice because the plunger was in roughly the same place. Nobody warned me these were different scales.

A quibble on your dead-space figure. You give two to seven microlitres for insulin-type needles, which is right for fixed-needle syringes, but the detachable pen needle plus syringe hub combinations sold in this market are considerably worse and you should say so.

A small thing but it matters in practice: your table gives amylase and lipase rising as a finding of unclear significance. In my laboratory we no longer report amylase at all for suspected pancreatitis, because lipase is more sensitive and more specific and having both invites the wrong one to be acted on.

My ferritin fell from 118 to 34 across a year on treatment and I was told this was expected because inflammation had fallen. Six months later I was clearly iron deficient. I appreciate the section on this being ambiguous, but the ambiguity was resolved in one direction and nobody looked.

My HbA1c was 6.1 before starting and 6.0 after four months. My clinic recorded this as no improvement in glycaemic control. My continuous monitor says my average glucose fell by a fifth over the same period. Which is measuring what?

You describe the low-T3 pattern during energy restriction as benign adaptation. There is a body of opinion holding that it represents a genuine hypometabolic state requiring treatment. I do not hold that view but your readers will encounter it.

Your table lists orforglipron with a half-life of 29 to 49 hours. That is a wide range to report as a single figure. What accounts for it?

Your piece states that moving the injection day does not change total exposure, and I accept the arithmetic, but I want to record that it changed my experience considerably. I moved from Monday morning to Thursday evening and the two worst days now fall on a weekend. The drug is doing the same thing; my week is not.

I have read three separate articles this month describing cagrilintide as a GLP-1 agonist and one describing tirzepatide as "semaglutide with an extra bit". Thank you for the glossary. Please run it again.

The claim that nothing at baseline predicts response is too strong. Surely baseline BMI, sex and diabetes status shift the expected outcome — the trials stratify on exactly those variables.

I found the section on the area postrema genuinely clarifying. I had assumed nausea was a stomach problem and had been treating it as one, unsuccessfully, for four months.

You say no company reports residual moisture. I obtained a figure from a supplier last year without difficulty, on request, so the data exists in at least some cases. The problem may be less that it is not measured than that it is not printed.

I have shipped temperature-sensitive material commercially for eleven years and your coolant arithmetic is right but generous. You assume the pack starts fully frozen. In practice packs are pulled from a freezer that is opened forty times a day, and a pack that starts at minus four with a soft core has lost a fair share of its budget before the box is closed.

Your table of degradation pathways lists racemisation and then says it is essentially never reported. If it is never reported, on what basis do you list it as a real risk rather than a theoretical one?

The mean kinetic temperature explanation is the clearest I have read anywhere, including in the training my employer paid for. I have printed the sidebar and put it on the wall of the dispatch room.

On amber glass: it is not merely cheap, it is standard in the wider chemical supply trade for anything with a chromophore. The fact that this market ships peptides in clear glass is a sign of who is doing the filling more than of any decision about photostability.

You report the STEP 1 nausea figure as approximately forty-four per cent. The publication gives 44.2 per cent. Given how much of your argument rests on precision about what these numbers mean, the rounding sits oddly.

I stopped at week six because I could not keep anything down for three days, and my prescriber told me I had not given it a fair chance. Reading your definition of dose-limiting, I think what happened was that nobody offered me the option of going back to the lower dose. It was escalate or stop.

Your figures show diarrhoea at thirty-two per cent and constipation at twenty-three per cent in the same trial arm. I assumed one of these was an error until your mechanism section. It would be worth putting that explanation before the table rather than after it.

You write that recombinant factor C is insensitive to the glucan branch of the cascade. It would be worth adding why anybody cares: cellulose filter media and certain paper wrappings shed glucans, and a laboratory that has chased a false positive through three repeat assays will never willingly go back to a reagent that responds to them.

I have read your protein tables twice and I still cannot work out what I should eat. I appreciate that this is the honest position but it is not a useful one for a person in a supermarket.

You write that leucine and isoleucine cannot be distinguished by tandem mass spectrometry. That is too absolute. Side-chain fragmentation under high-energy conditions produces diagnostic w and d ions, and the discrimination has been demonstrated repeatedly.

I have spent a week trying to reconcile a certificate’s stated mass of 4113.6 with a figure of 4111.1 I calculated from the sequence, and had convinced myself something was wrong with the vial. It was the isotope convention. Thank you, and also: how is this not stated on every certificate in existence?

You give the glutamine-to-lysine difference as 0.036 daltons and say it needs an orbital trap. In practice you also need the two species to be chromatographically separated or present in a sensible ratio, because at one per cent of the parent intensity the minor peak sits on the shoulder of the isotope envelope regardless of resolving power.

Three months after stopping, my HbA1c had barely moved and I concluded I had got away with it. Six months after stopping, it was back where it started. Your point about the lag is the single most useful sentence I have read on this subject.

Your fortnightly arithmetic table is correct but I think it understates the practical point. A fourfold peak-to-trough swing is not merely lower average exposure; it is a different drug experience, with the last few days of each cycle spent at a concentration the person has effectively titrated off.

I take this for kidney disease, not for weight. Every piece of writing I encounter about stopping is about the weight coming back. It has taken me a year to find anybody willing to say plainly that the renal benefit accrued over years of treatment and nobody has tested what happens if I stop.

The claim that stopping does not leave you worse off than baseline is a group-level claim about trial arms. Individuals can and do overshoot. Your phrasing invites readers to conclude otherwise.

You say no dose-equivalence data exists between agents in this class. During the shortage my pharmacy substituted one for another on the basis of a conversion table they had printed from somewhere. Where would such a table have come from?

I have a certificate with an expiry date twenty-four months from manufacture and no stability data behind it, which your article says is a claim the documentation cannot support. The supplier tells me it is industry standard. Is it?

On the accreditation-scope point: most private buyers will not know which accreditation body to search. It would be more useful to publish the four or five registers that cover the laboratories this market actually uses than to tell readers the registers exist.

You describe reused chromatogram images as a tell. I work in a contract laboratory and I would note that some data systems export a representative overlay rather than the individual injection, so identical-looking traces can occur legitimately across a batch series. It is still worth asking about; it is not the smoking gun your article implies.

Your needle-length section says four millimetres is adequate for all adults, which contradicts what I was told by a nurse who insisted on half an inch because of my weight. Which is right?

You recommend writing the concentration on the vial. I would add: write it on the box as well. My vial label came off in the fridge and I lost the only record of what diluent volume I had used.